MKI67 and neoplasm: As shown in Fig. 7, the densities of Ki67+ tumor cells and CC3+ tumor cells were not significantly altered by anti-PD-1 therapy when considering all patients in aggregate; however, there were two patients who did demonstrate a significant decrease in Ki67+ tumor cells in response to intralesional pembrolizumab.